Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

109.64 -4.90 (-4.28%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 11, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
61 62 Next >
Gilead Sciences, Inc. proudly Supports Unite for HER's Metastatic Breast Cancer Sustainer Program
June 26, 2025 -- Transformative Integrative Breast Cancer Care Program Supports Metastatic Breast Cancer Patients Nationwide 
Via 24-7 Press Release
4 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Gilead Sciences Signs $750M Deal For Cancer Drug With Kymera Therapeutics, Predicts Hit To Its Annual Profit
Under the terms of the agreement, Kymera is eligible to receive up to $750 million in total payments, including up to $85 million in upfront and potential option exercise payments. 
Via Stocktwits
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
Via ACCESS Newswire
Gilead Bets On Kymera's CDK2 Molecular Glue Degrader For New Cancer Therapies
Kymera signs $750 million CDK2 drug deal with Gilead and earns $20 million from Sanofi as KT-485 advances toward clinical trials in inflammatory diseases. 
Via Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
Via Benzinga
Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders
From Gilead Sciences, Inc.
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
Via ACCESS Newswire
If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today
Via Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
From Pomerantz LLP
Via GlobeNewswire
5 Insightful Analyst Questions From Gilead Sciences’s Q1 Earnings Call
Gilead Sciences’ first quarter performance saw sales remain flat year over year, which did not meet Wall Street’s revenue expectations and prompted a negative market reaction. Management attributed the... 
Via StockStory
Topics Earnings Intellectual Property World Trade
The FDA Shake-Up Continues, And Could Impact Genetic Medicines
Nicole Verdun and Rachael Anatol were placed on administration leave without explanation. 
Via Investor's Business Daily
Topics Government
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
Via ACCESS Newswire
FDA Approves Gilead's 'Game Changing' Twice-Yearly Shot To Prevent HIV Transmission, Critics Slam $28K Price Tag
Gilead's FDA-approved Yeztugo, a twice-yearly injectable HIV PrEP, showed near-perfect trial efficacy but faces backlash over its $28K annual price. 
Via Benzinga
GILEAD SCIENCES INC (NASDAQ:GILD) – A Quality Stock Worth Considering
GILEAD SCIENCES INC (NASDAQ:GILD) is a quality stock with strong profitability, high ROIC, and reasonable valuation, making it a candidate for long-term investors. 
Via Chartmill
Gilead Earns Analyst Praise As FDA Clears Yeztugo For Biannual HIV Prevention
Analysts at Oppenheimer, BMO, Morgan Stanley, and Mizuho weighed in with positive long-term views, though Oppenheimer flagged near-term headwinds tied to court risks and cannibalization of existing... 
Via Stocktwits
Gilead Sciences Wins Approval For Highly Effective HIV Prevention Drug
The drug will sell under the brand name Yeztugo. In clinical testing, it kept 99.9% of patients from contracting HIV. 
Via Investor's Business Daily
Yeztugo® (Lenacapavir) Is Now the First and Only FDA-Approved HIV Prevention Option Offering 6 Months of Protection
From Gilead Sciences, Inc.
Via Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
From Pomerantz LLP
Via GlobeNewswire
Gilead's HIV Prevention Drug Could Be Manufactured At Shocking Low Cost: Report
Lenacapavir, a twice-yearly HIV prevention shot by Gilead, could be produced for $25 a year but may sell for $25K, raising concerns over global access and equity. 
Via Benzinga
GILEAD SCIENCES INC (NASDAQ:GILD) – A potential undervalued opportunity in biopharma
GILEAD SCIENCES (NASDAQ:GILD) appears undervalued with strong profitability and reasonable growth, making it a candidate for value investors. The stock trades below industry averages on key valuation... 
Via Chartmill
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc. - GILD
From Pomerantz LLP
Via GlobeNewswire
Jefferies Names Akero Therapeutics, Scholar Rock As Biotech Companies With Takeover Potential, But Retail Isn’t Pleased
Jefferies thinks big pharma companies are "still on the hunt" for deals. 
Via Stocktwits
1 Unpopular Stock that Deserves a Second Chance and 2 to Keep Off Your Radar
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can... 
Via StockStory
Why Gilead Scinces Stock Tumbled on Tuesday
Via The Motley Fool
Gelteq Stock Soars On Deal With Healthy Extracts For Product Distribution In North America: Retail Chatter Explodes
The agreement names Healthy Extracts as Gelteq’s exclusive North American storage, shipping, and fulfillment partner. 
Via Stocktwits
US FDA Places Clinical Hold On Gilead Trials Of Two Investigational HIV Treatments: Retail’s On The Fence
The clinical hold is due to the identification of a safety signal, characterized by decreases in CD4+ T-cell (CD4) and absolute lymphocyte counts, in certain participants receiving the combination of... 
Via Stocktwits
2 Reasons to Like GILD (and 1 Not So Much)
While the broader market has struggled with the S&P 500 down 2.4% since December 2024, Gilead Sciences has surged ahead as its stock price has climbed by 21% to $111.47 per share. This performance may... 
Via StockStory
Topics Stocks
Gilead's HIV Pipeline Gains Traction With Upcoming FDA Decision For HIV-1 Drug
Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S. PrEP users by 2035. 
Via Benzinga
1 Healthcare Stock Worth Your Attention and 2 to Turn Down
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, and over the past six... 
Via StockStory
Topics Stocks
< Previous 1 2 3 4 5 6 7 8 9
...
61 62 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.